Search results
Vaccine Sales Are Falling. Should You Still Buy Pfizer?
Motley Fool· 12 months agoPfizer (NYSE:PFE) confirmed this week what everyone has been expecting. The big pharmaceutical...
A combination vaccine for flu and COVID-19 is in the works. Here's what to know.
USA TODAY via Yahoo News· 1 year agoAs the holiday season draws near, more Americans may be sporting two Band-Aids after receiving both...
Who should get the new COVID vaccines? What to know about the 2023-2024 shots
Live Science via Yahoo News· 8 months agoA syringe is filled with Pfizer-BioNTech Covid-19 vaccine by a woman in blue surgical gloves. Like...
Moderna Is Suing Pfizer And BioNTech, Alleging They Stole mRNA Technology For COVID Vaccines
BuzzFeed News via Yahoo News· 2 years agoModerna on Friday filed twin lawsuits in US federal court and in Germany against rivals Pfizer and...
Moderna sues Pfizer, BioNTech over COVID-19 vaccine patents
WFXT via Yahoo News· 2 years agoCOVID-19 vaccine maker Moderna is suing Pfizer and the German drugmaker BioNTech, accusing its main...
3 doses of COVID vaccine are effective for kids under 5, Pfizer says
TODAY via Yahoo News· 2 years agoThree doses of Pfizer-BioNTech’s COVID-19 vaccine for the youngest children were 80% effective...
Pfizer/BioNTech Covid-19 booster approved by UK medicines regulator
Press Association News via AOL· 2 years agoAn updated Covid-19 booster vaccine has been approved for use in the UK. The second “bivalent”...
Moderna accuses Pfizer/BioNTech of patent infringement over the tech behind its COVID vaccine
WFXT via Yahoo News· 2 years agoA legal battle is brewing between makers of vaccines against COVID-19. Cambridge-based Moderna is...
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
Reuters via Yahoo Finance· 2 years agoModerna is suing Pfizer and its German partner BioNTech for patent infringement in the development...
This May Be Pfizer's Key to Long-Term Vaccine Dominance
Motley Fool· 2 years agoPfizer (NYSE: PFE) is already the leader in the coronavirus vaccine space. Rival Moderna (NASDAQ: MRNA) has a significant position in the market. Latecomer Novavax (NASDAQ: NVAX) could also take market share in the months to come.
